Effect of lipid-lowering therapy on vasomotion and endothelial function

Current Cardiology Reports

Volumn 1, Issue 3, 1999, Pages 238-243

  Kinlay, Scott ^a   Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE;

ADRENERGIC SYSTEM; ARTERIOSCLEROSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VASOMOTOR SYSTEM;

EID: 0033186439     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0029-5     Document Type: Article

References (59)

1. The Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
3. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
4. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
5. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Jama 1998, 279:1615-1622.
6. Wissler RW, Vesselinovitch D: Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animal models. Am J Cardiol 1990, 65:33F-40F.
7. Kinlay S, Selwyn AP, Delagrange D, et al.: Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996, 7:389-397.
8. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995, 91:844-850.
9. Plutzky J: Atherosclerotic Plaque Rupture: Emerging Insights and Opportunities. Am J Cardiol 1999, 84(1A):155-205.
10. Kinlay S, Ganz P: Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol 1997, 80:11I-16I.
11. Ignarro LJ, Byrns RE, Buga GM, Wood KS: Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987, 61: 66-79.
12. Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664-666.
13. RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
14. Selwyn A P, Kinlay S, Creager M, et al.: Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol 1997, 79:17-23.
15. Meredith I, Yeung A, Weidinger F, et al.: Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993, 87 (Suppl V): V56-V66.
16. Ludmer PL, Selwyn AP, Shook TL, et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
17. Cox DA, Vita JA, Treasure CB, et al.: Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989, 80:458-465.
18. Celermajer DS, Sorensen KE, Gooch VM, et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
19. Creager MA, Cooke JP, Mendelsohn ME, et al.: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990, 86:228-234.
20. Gryglewski RJ, Palmer RM, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456.
21. Liao JK, Shin WS, Lee WY, Clark SL: Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995, 270:319-324.
22. Nabel EG, Selwyn AP, Ganz P: Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990, 16:349-356.
23. Vita JA, Treasure CB, Nabel EG, et al.: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990, 81: 491-497.
24. De Caterina R, Libby P, Peng HB, et al.: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96:60-68.
25. Kubes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991, 88:4651-4655.
26. Tsao PS, Buitrago R, Chan JR, Cooke JP: Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996, 94:1682-1689.
27. Collins T, Read MA, Neish AS, et al.: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. Faseb J 1995, 9899-909.
28. Marui N, Offermann MK, Swerlick R, et al.: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993, 92:1866-1874.
29. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R: Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995, 76:980-986.
30. Tsao PS, Wang B, Buitrago R, et al.: Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997, 96:934-940.
31. Peng HB, Rajavashisth TB, Libby P, Liao JK: Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995, 270:17050-17055.
32. Azuma H, Ishikawa M, Sekizaki S: Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986, 88:411-415.
33. Hogan JC, Lewis MJ, Henderson AH: In vivo EDRF activity influences platelet function. Br J Pharmacol 1988, 94:1020-1022.
34. Yao SK, Ober JC, Krishnaswami A, et al.: Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992, 86:1302-1309.
35. Shireman PK, McCarthy WJ, Pearce WH, et al.: Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. J Vasc Surg 1996, 23:810-817; discussion 817-818.
36. Robbie LA, Booth NA, Brown AJ, Bennett B: Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996, 16:539-545.
37. Gordon JB, Ganz P, Nabel EG, et al.: Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 1989, 83:1946-1952.
38. Nabel EG, Selwyn AP, Ganz P: Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 1990, 81: 850-859.
39. Quyyumi AA, Dakak N, Andrews NP, et al.: Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995, 92:320-326.
40. Egashira K, Inou T, Hirooka Y, et al.: Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993, 91:29-37.
41. Lieberman EH, Gerhard MD, Uehata A, et al.: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994, 121:936-941.
42. Zeiher AM, Drexler H, Wollschlager H, Just H: Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991, 83:391-401.
43. Egashira K, Hirooka Y, Kai H, et al.: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
44. Anderson TJ, Meredith IT, Yeung AC, et al.: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488-493.
45. Leung WH, Lau CP, Wong CK: Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993, 341:1496-1500.
46. Treasure CB, Klein JL, Weintraub WS, et al.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481-487.
47. Huggins GS, Pasternak RC, Alpert NM, et al.: Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998, 98:1291-1296.
48. Andrews TC, Raby K, Barry J, et al.: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997, 95:324-328.
49. van Boven AJ, Jukema JW, Zwinderman AH, et al.: Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996, 94:1503-1505.
50. Seiler C, Suter TM, Hess OM: Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol 1995, 26:1615-1622.
51. Kroon AA, Aengevaeren WR, van der Werf T, et al.: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826-1835.
52. O'Driscoll G, Green D, Rankin J, et al.: Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997, 100: 78-684.
53. Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
54. Pitt B, Waters D, Brown WV, et al.: Aggressive lipid-lowering therapy combined with angioplasty in stable corinary artery disease. N Engl J Med 1999, 341:70-76.
55. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
56. Laufs U, Fata VL, Liao JK: Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997, 272:31725-31729.
57. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al.: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101: 2711-2719.
58. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reductio (see comments). JAMA 1998, 279:1643-1650.
59. Williams JK, Sukhova CK: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998, 31:684-691.